The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease
Ziad A. Massy(Inserm), Silke Röser, Anke Torp, Nikolaus Frischmuth, Nicholas C Chesnaye(Amsterdam Neuroscience), Christian Marx, Kai Hahn, Justyna Mazur, Ines Schlee, Sabine Aign, Claudia Torino(Istituto di Fisiologia Clinica), Kirsten Anding‐Rost, Katja Blouin, Holger Naujoks, Christoph Wanner(Universitätsklinikum Würzburg), Eva Platen, Jean‐Claude Alvarez(Inserm), Marie Evans(Karolinska University Hospital), Monika Hopf, Pawlos Ichtiaris, Kitty J. Jager(Amsterdam University Medical Centers), Katrin Neumeier, Christiane Drechsler(Universitätsklinikum Würzburg), Andreas Schneider, Petra Kirste, Sabine Cäsar, Islam Amine Larabi(Inserm), Gaetana Porto(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Petra Schulz, Sandra Biribauer, Sherin Manan, Boris Perras, Dunja Fuchs, Beate Iwig, Joachim Beige, Nadja Wuttke, Maciej Szymczak(Wroclaw Medical University), Friedo W. Dekker(Leiden University Medical Center), Hendrik Schlee, Fergus Caskey, Claudia Emde, Christof Blaser, Detlef H. Krieter(Universitätsklinikum Würzburg), Hans Schmidt‐Gürtler, Ellen Irmler, Lothar Schramm, Jochen Röthele
Cited by 17
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886